ReviewFrontiers in pharmacology2026
Renal anemia: from erythropoietin deficiency to erythropoietin resistance.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal anemia is one of the core complications of chronic kidney disease (CKD) and is closely associated with poor patient prognosis. Renal interstitial fibrosis or impaired oxygen sensing leads to insufficient erythropoietin (EPO) production, which constitutes the fundamental mechanism initiating renal anemia. On this basis, multiple pathological factors-including the inflammatory microenvironment in CKD, iron deficiency, and mineral and bone disorders-synergistically induce EPO resistance, further exacerbating anemia and diminishing the response to existing therapies. Currently, the treatment of renal anemia has moved beyond simple EPO replacement and is progressively shifting toward a dual strategy that emphasizes both correction of EPO resistance and enhancement of drug responsiveness. This article summarizes the molecular network through which insufficient EPO synthesis and EPO resistance synergistically aggravate renal anemia, systematically reviews the pharmacological basis, limitations, and safety risks of current drug therapies, and discusses future research directions and potential therapeutic targets in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.